InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,064.20
(
0.91%
)
US TECH 100
17,171.20
(
1.84%
)
Dow Jones
38,225.66
(
0.85%
)
Brent Oil
83.63
(
0.11%
)
Bitcoin
58,839.98
(
1.03%
)
Post# of 251689
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119553
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 197737

Monday, 03/06/2017 5:33:34 PM

Monday, March 06, 2017 5:33:34 PM

Post# of 251689
(MNTA)—UK Court invalidates ABBV’s Humira “use” patents on three indications:

http://www.cnbc.com/2017/03/05/uk-court-delivers-high-stakes-decision-on-worlds-best-selling-drug.html

The ruling determined that AbbVie's indications pertaining to rheumatoid arthritis, psoriasis and psoriatic arthritis were unpatentable.

Although today’s UK judgment not affect the enforceability of ABBV’s US patents, I expect a similar outcome when ABBV’s US method of use patents for Humira are tested in court, as noted in #msg-118781959.

The plaintiff in the UK lawsuit was Samsung Bioepis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up